Without a publicly indexed compendial monograph under the designation Changqing Kechong Powder, the material is specified by the manufacturer’s certificate of analysis, the API master file, and the intended multi-dosage-form processing envelope: tablets, injections, capsules, powders, granules, premix, and solutions. The product model identifier Changqing Kechong Powder Veterinary Grade API does not correspond to a finished dosage form and is not assigned a national drug code in this description. Published data for this specific configuration is limited; therefore batch release parameters and stability-defining characteristics must be confirmed from the CoA and supplier qualification file.

Physical presentation is a non-sterile veterinary-grade powder with controlled particle size distribution. Typical specification fields include appearance, identification by retention time and spectral match, assay on the dried basis, individual and total related substances, loss on drying, residue on ignition, elemental impurities, residual solvents, water content by Karl Fischer titration, and microbial enumeration. Additional parameters for parenteral-grade material include bacterial endotoxins and particulate matter testing of the final solution. The analytical matrix below lists the method designations and typical veterinary API acceptance criteria; the current CoA remains the controlling document.

Granulation and Compression Behavior in Multi-Dosage-Form Manufacturing

For tablet and capsule manufacture, the powder is normally dry-blended in a V-blender or bin blender at 15–25 rpm for 10–20 min before direct compression or dry granulation. Low-dose formulations require geometric dilution with a suitable diluent such as anhydrous lactose or microcrystalline cellulose to achieve content uniformity conforming to USP <905>. The particle size distribution is controlled by laser diffraction under ISO 13320:2020; for direct compression, a D90 below 150 µm is commonly specified to reduce segregation and capping. For high-shear wet granulation, purified water or a hydroalcoholic binder solution is added at an impeller speed of 100–300 rpm, with granulation endpoint determined by impeller torque or power consumption rather than fixed time. If moisture uptake at relative humidity above 60% has occurred, a pre-drying step is required before blending; the material should not be processed at high moisture because flow decay and content non-uniformity can result.

Compression parameters on a rotary tablet press should be adjusted to a target hardness of 6–12 kp for non-friable tablets meeting USP <1216>. Preformulation compaction studies are required because the active moiety may exhibit plastic deformation or brittle fracture depending on particle morphology and residual water. Capsule filling on a dosator or tamping-pin machine requires flowable powder or granulated material; a Hausner ratio below 1.25 is generally expected before encapsulation to maintain fill weight variability below 2.0% relative standard deviation. For granules, a dry granulation step using a roller compactor with a roll pressure of 20–50 bar may be used if the powder lacks sufficient flow or bulk density for direct compression; the resulting granules should be milled and sieved to a target granule size of 250–850 µm to avoid segregation in the tablet press hopper. For continuous twin-screw granulation, equipment with an L/D ratio of 25:1–40:1 is used; screw speed and liquid-to-solid ratio are set to maintain torque below the machine limit, and pilot trials are required because published data for this specific configuration is limited.

Comparisons against uncontrolled technical-grade powders require particle size distribution, impurity profile, residual solvent, and endotoxin data to be reviewed together rather than as isolated values. Technical-grade materials frequently exhibit D90 values above 250 µm, total aerobic microbial counts above 10⁴ CFU/g, and residual solvent levels exceeding USP <467> Class 2 options. The veterinary API grade is differentiated by a narrower particle size distribution, tighter related-substance limits, lower water content, and qualification for multiple dosage forms including injections. In addition, the batch-to-batch variance in particle size and impurity profile is usually narrower for the API grade, which reduces the need for real-time process correction on high-speed manufacturing lines.

In formulation practice, the veterinary grade can be used directly in dry blending and solution preparation without prior recrystallization or solvent washing in most cases. Uncontrolled technical powder frequently requires additional milling, recrystallization, or drying before pharmaceutical processing because its particle size and residual solvent profile do not meet compendial or good manufacturing practice expectations. The comparative matrix below summarizes the distinctions under standard test conditions; site-specific CoA values should be used for release decisions.

What Limits Direct Use of the Powder in Injectable Formulations?

Injectable solution manufacture imposes bacterial endotoxin and particulate burden limits that are not automatically met by every powder batch. The powder is not sterile upon receipt; terminal sterilization of a moisture-sensitive solution may alter the active moiety, so sterile filtration through a 0.22 µm polyvinylidene fluoride membrane is used after dissolution and pH adjustment. The solution must be prepared in a controlled environment equivalent to EU GMP Grade C or better, with particle cleanliness consistent with ISO 14644-1. Pre-filtration bioburden samples are taken before the sterilizing filter, and the dissolved API should be particle-free before filtration. If insoluble material is observed, the solution may require depth filtration or prolonged low-shear mixing. For parenteral-grade material, the manufacturer’s CoA should include bacterial endotoxin by USP <85>, with a limit calculated from the maximum intended dose. If the powder is supplied only as a non-parental grade, additional depyrogenation such as activated carbon treatment or ultrafiltration may be required, but these operations can reduce assay and must be validated for recovery.

For injectable solutions, aqueous solubility should be determined at 20–25°C and over the intended pH range. If the target concentration is not achieved in water, a co-solvent system of propylene glycol, glycerin, or polyethylene glycol 400 may be used, provided the solution is physically stable and free from precipitation during storage. Incompatibility with buffer salts or pH modifiers should be evaluated by stress testing; the final solution should be filtered through a 0.22 µm membrane and filled aseptically. Terminal heat sterilization should be avoided unless the active moiety is known to be thermostable and the container-closure system is qualified. The maximum holding time for the filtered solution before filling should be limited by bioburden and chemical stability data.

When Dry-Heat Exposure Exceeds Pharmacopoeial Limits

When dry-heat exposure exceeds the manufacturer’s stated maximum, the powder may undergo polymorphic transition, loss of residual water, or related-substance increase. The material should not be dried above the temperature stated on the CoA; if a drying step is necessary due to moisture uptake at relative humidity above 60%, a vacuum dryer or fluid-bed dryer operating at 40–50°C for a batch-specific time is preferred over tray drying. Overdrying can reduce residual moisture below the equilibrium water content required for good tablet compactibility, leading to capping or lamination on high-speed rotary presses. The product temperature during drying should be monitored with calibrated probes, and each batch should be sampled after drying to confirm that loss on drying and related substances remain within specification.

Thermal processing in granulation or coating should be limited by the active moiety’s degradation kinetics. If the CoA specifies a maximum processing temperature of 60°C, inlet air temperature for fluid-bed granulation should be set no higher than 55°C to maintain product temperature within the specified boundary. For solution preparation, heating should be discontinuous and controlled by jacketed vessels with temperature probes; excursions above the limit must be investigated as a deviation because related substances may increase beyond the shelf-life specification. In addition, the powder should not be exposed to direct steam for sanitization or to strong oxidizing agents that may react with the active moiety.

Veterinary Premix Carrier Incompatibilities and Assay Uniformity

Carrier selection and particle size mismatch for feed premix and oral powder manufacture influence assay uniformity and segregation. The API is mixed with carriers such as ground corn, rice hulls, or lactose monohydrate; a carrier with a particle size range of 150–850 µm and low electrostatic charge is generally suitable. Segregation during transfer and bag filling occurs when the API D90 is far below the carrier D50, producing flow-induced separation. This is controlled by a two-stage mixing process: an intermediate mix or premix concentrate at 1:10 or 1:20 dilution is prepared in a ribbon blender for 10–15 min, then diluted to the final feeding concentration in a second mixing step. The final blend should be sampled at 10 or more points and tested for assay; acceptance is typically 90%–110% of labeled concentration with a relative standard deviation below 5.0%.

Incompatibilities may arise with acidic carriers, metal-ion-containing mineral supplements, or amine-based additives. If the active moiety is acid-labile or metal-sensitive, the premix formulation should avoid uncoated iron or copper salts unless compatibility studies demonstrate no degradation. Moisture from hygroscopic carriers such as molasses-based carriers can raise water activity and accelerate hydrolysis; thus, the water activity of the finished premix should be controlled below the limit specified in the product development report. In addition, the final premix should be protected from light if the API is photolabile, and packaging materials should be selected to maintain water vapor barrier properties.